Antinuclear antibodies appearing during PUVA therapy

Area of Science:

• Dermatology
• Immunology
• Phototherapy

Background:

• Psoralen plus ultraviolet A (PUVA) is a common phototherapy for skin conditions.
• Antinuclear antibodies (ANA) are associated with autoimmune and connective tissue diseases.
• The potential for PUVA to induce or alter ANA levels in patients is not fully understood.

Purpose of the Study:

• To investigate the incidence and characteristics of antinuclear antibodies (ANA) in patients undergoing PUVA therapy.
• To determine if PUVA treatment significantly affects ANA titres or patterns.
• To assess the clinical significance of ANA development during PUVA therapy.

Main Methods:

• Prospective study of patients receiving PUVA therapy.
• Collection of ANA data before and during PUVA treatment.
• Comparison of ANA status in PUVA patients versus a control group.
• Clinical and laboratory evaluation of patients who developed ANA.

Main Results:

• ANA were detected in 8% of patients considered for PUVA prior to therapy.
• ANA developed in 34% of patients during PUVA treatment.
• A statistically significant increase in ANA titres was observed during PUVA therapy compared to baseline.
• One patient developed nucleolar ANA with symptoms suggestive of collagen vascular disease; others had low-titre homogeneous ANA.

Conclusions:

• PUVA therapy is associated with the induction of antinuclear antibodies.
• The majority of induced ANA are low-titre and homogeneous, with low clinical significance.
• Close monitoring is warranted for patients developing ANA during PUVA, particularly for those with specific patterns or symptoms.